glp-1 obesity drug news today september 2025 ISPOR 2025: Exploring reasons for discontinuation The GLP-1 Revolution Continues
Description
Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
What is the status of eye drops containing beta-blockers
This clinical trial did not include patients with T2D, and the emerging data suggests that the weight-loss effects of tirzepatide are reduced in patients with diabetes, a difference also observed in trials with 2.4 mg of semaglutide 2
Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes
